Our findings align well with other studies of single-agent immune checkpoint inhibitors in advanced osteosarcoma [13–17] and confirm that osteosarcomas generally show primary resistance to treatment targeting PD-1/PD-L1, both in adult and pediatric patient cohorts. The gene discussed is PDCD1; the disease is osteosarcoma.